{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:38:27Z","timestamp":1787071107803,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Primary gastric lymphomas, which make up the vast majority of extranodal non-Hodgkin lymphoma, are rare and the most common subtype is primary gastric diffuse large B-cell lymphoma (PG-DLBCL). In our study, we investigated the clinical and prognostic factors of this lymphoma type as a single-center experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Between January 2001 and February 2021, 91 patients aged \u226518 years, registered with the diagnosis of primary gastric DLBCL, diagnosed histopathologically, and whose evaluation parameters were reached, were retrospectively scanned.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age of 91 patients with a diagnosis of PG-DLBCL was 58 (20\u201381, minimum\u2013maximum) years. Of the patients, 64.8% were men and 35.2% were women. While the number of patients with an International Prognostic Index (IPI) score of 0\u20132 (low\u2013low-intermediate risk) was 54 (59.4%), the number of patients with an IPI score of 3 (high intermediate) was 19 (20.9%), and the number of patients with an IPI score of 4\u20135 (high risk) was 18 (19.8%). While 52.7% of the patients had a complete response, 20.9% had a partial response, 3.3% had stable disease, and 23.1% had progressive disease. The 10-year event-free survival (EFS) and overall survival (OS) rates for all patients, respectively, were 52.1% and 53.2%. We found factors affecting survival in univariate analysis; age groups (\u226460\/&gt;60), ECOG groups (0-1\/\u22652), Lugano stage (I-II\/III-IV), LDH level (normal\/high), IPI risk groups (low\/low-intermediate\/high-intermediate\/high) and radiotherapy (yes\/no). In multivariate analysis, only; age groups (\u226460\/&gt;60) and IPI risk groups (low\/low-intermediate\/high-intermediate\/high) were found to be independent factors affecting survival. In addition, in our study, we determined that the division of the IPI intermediate risk group into low intermediate and high intermediate is one of the factors predicting prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Few studies of PG-DLBCL have investigated the long-term survival rates of patients and primarily examined small patient groups because of the low incidence of the disease. In our study, we think that detailed evaluation of age and especially IPI risk groups play a role in predicting survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_2111_21","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T10:51:34Z","timestamp":1689763894000},"page":"778-782","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of clinical and prognostic factors for primary gastric diffuse large B-cell lymphoma: Single-center experience"],"prefix":"10.4103","volume":"19","author":[{"given":"Murat","family":"Bardakci","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya Demirtas","family":"Esmer","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Hafizoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Karaman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Faruk","family":"Kuzu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Karakas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Gungorer","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogan","family":"Uncu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3748\/wjg.v17.i6.697","article-title":"Primary gastrointestinal lymphoma","volume":"17","author":"Ghimire","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1073274818778256","article-title":"Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment","volume":"25","author":"Ju\u00e1rez-Salcedo","year":"2018","journal-title":"Cancer Control"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.21873\/anticanres.14616","article-title":"EBV positivity and programmed death-ligand 1 expression in diffuse large B-cell lymphoma: A systematic review","volume":"40","author":"Barzyk","year":"2020","journal-title":"Anticancer Res"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MCG.0b013e3181b4b1ab","article-title":"Primary low-grade and high-grade gastric MALT-lymphoma presentation","volume":"44","author":"Zullo","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"e929898","DOI":"10.12659\/MSM.929898","article-title":"Aprognostic model of gastrointestinal diffuse large B cell lymphoma","volume":"27","author":"Gao","year":"2021","journal-title":"Med Sci Monit"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-020-01391-9","article-title":"Gastric diffuse large B-cell lymphoma: A single-center 9-year experience","volume":"37","author":"Couto","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1177\/1078155218809458","article-title":"Primary gastric diffuse large B-cell lymphoma: The role of dose-dense chemotherapy","volume":"25","author":"Avil\u00e9s","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3897\/folmed.62.e51402","article-title":"Absolute monocyte and platelet counts may provide additional prognostic \u0131nformation in primary gastric diffuse large B-cell lymphoma patients treated with rituximab and CHOP","volume":"62","author":"Spassov","year":"2020","journal-title":"Folia Med (Plovdiv)"},{"key":"R9-20241021","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5963607","article-title":"Prediction of overall survival and progression-free survival by the 18F-FDG PET\/CT radiomic features in patients with primary gastric diffuse large B-cell lymphoma","author":"Zhou","year":"2019","journal-title":"Contrast Media Mol Imaging 2019"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored \u0131nternational working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1038\/bcj.2014.40","article-title":"Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity","volume":"4","author":"Kuo","year":"2014","journal-title":"Blood Cancer J"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/medicina57050498","article-title":"Prognostic \u0131mpact of pretreatment 2-[18F]-FDG PET\/CT parameters in primary gastric DLBCL","volume":"57","author":"Albano","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R13-20241021","first-page":"3","article-title":"Primary gastric lymphoma types and pathological pattern: A tertiary hospital experience","volume":"43","author":"Alamer","year":"2021","journal-title":"Bahrain Med Bull"},{"key":"R14-20241021","first-page":"2","article-title":"Long term outcomes of early stage pr\u0131mary gastr\u0131c d\u0131ffuse large B-cell lymphoma: A mult\u0131-centre retrospect\u0131ve study","volume":"39","author":"Smith","year":"2021","journal-title":"Hematol Oncol"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"566","DOI":"10.17235\/reed.2017.4882\/2017","article-title":"Clinical manifestations and endoscopic presentations of gastric lymphoma: A multicenter seven year retrospective survey","volume":"109","author":"Cui","year":"2017","journal-title":"Rev Esp Enferm Dig"},{"key":"R16-20241021","first-page":"159","article-title":"Primary gastric diffuse large B-cell lymphoma","volume":"31","author":"Hung","year":"2008","journal-title":"Chang Gung Med J"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1080\/10428194.2018.1515942","article-title":"The size and depth of lesions measured by endoscopic ultrasonography are novel prognostic factors of primary gastric diffuse large B-cell lymphoma","volume":"60","author":"Liu","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00535-019-01616-3","article-title":"Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma","volume":"55","author":"Ishikawa","year":"2020","journal-title":"J Gastroenterol"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J Clin Oncol"},{"key":"R20-20241021","first-page":"614","article-title":"Clinical analysis of primary gastric diffuse large B-cell lymphoma","volume":"32","author":"Zhang","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"e0133469","DOI":"10.1371\/journal.pone.0133469","article-title":"Consolidation radiotherapy in stage IE- IIE, non-bulky primary gastric diffuse large B-cell lymphoma with post-chemotherapy complete remission","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"R22-20241021","article-title":"Trends in survival of patients with primary gastric diffuse large B-cell lymphoma: An analysis of 7051 cases in the SEER database","author":"Liu","year":"2018","journal-title":"Dis Markers 2018"},{"key":"R23-20241021","first-page":"602","article-title":"Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma","volume":"37","author":"Huang","year":"2016","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R24-20241021","first-page":"36","article-title":"Treatment and prognostic analysis of early stage of primary gastric diffuse large B-cell lymphoma","volume":"16","author":"Liu","year":"2013","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-hodgkin's lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N Eng J Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2111_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:41:34Z","timestamp":1787067694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_2111_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_2111_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2021-11-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}